Operational Inflection + GLP-1 Winner
A low‑priced consumer business currently in a turnaround is hitting an operational inflection point, with GLP‑1 drug adoption expected to accelerate growth. The company trades at roughly 4.7 × EBITDA and holds net cash equal to about half its market capitalization, creating a compelling risk‑reward profile. Daily trading volume sits around $6‑7 million, underscoring solid liquidity. The analyst recommends watching the stock as GLP‑1 trends could lift earnings further.
Special Situations Digest Is Spinning Off
The Special Situations Digest is moving from Substack to its own website, specialsitsdigest.com, with the first issue launching Sunday. The format and research remain unchanged, but the new platform adds cleaner navigation, category filters, and color‑coded situation cards. Access to...
Special Situations Digest - #2
The second Special Situations Digest highlights a wave of activist campaigns spanning technology, biotech, consumer, and industrial firms, alongside numerous companies embarking on strategic reviews or restructuring. Activists such as YZi Labs, Engine Capital, and Elliott Management are pushing for...